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Abstract
Background: Clinical studies comparing trabeculectomy augmented with Ologen implant (OLO) versus trabeculectomy
plus mitomycin-C (MMC) show contradictory results. To obtain long-term data, we report an extended 5-year follow-up
trial evaluating the safety and efficacy of OLO as adjuvant compared to low-dosage MMC in trabeculectomy.
Methods: Forty glaucoma patients (40 eyes) assigned to trabeculectomy with MMC or Ologen. Primary outcome: target
IOP at ≤21, ≤17 and ≤15 mmHg; complete and qualified success endpoint rates. Secondary outcomes: visual acuity (VA),
mean deviation (MD), bleb evaluation, according to Moorfields Bleb Grading System (MBGS); spectral domain
OCT (SD-OCT) bleb examination; number of glaucoma medications; frequency of postoperative complications.
Results: The mean preoperative IOP was 26.7(±5.2) in MMC and 27.3(±6.0) in OLO eyes. Mean 60-month
percentage reduction in IOP was significant in both groups [40.9 (±14.2) and 42.1(±13.3) P = 0.01], with an
endpoint value of 15.2 (±3.2) and 15.8 (±2.3) mmHg in MMC and OLO, respectively. Complete success rates
at ≤ 21 mmHg target IOP were 65 % and 70 %, at ≤17 mm Hg 60 % and 55 %, and at the ≤15 mm Hg
target IOP 35 % and 45 % in MMC and OLO, respectively.
The Kaplan–Meier curves did not differ both for complete and qualified success at any target IOP, with no
significant endpoint intergroup difference at ≤ 15 mm Hg (log-rank P = 0.595).The intergroup MBGS scores
differed due to reduced central and peripheral vascularity in MMC group (P = 0.027; P = 0.041).
SD-OCT analysis denied differences in bleb height between MMC vs OLO (140.5 ± 20.3 μ vs 129.2 ± 19.3 μ
respectively; P =0.079).
Mean antiglaucoma medications were significantly reduced (P < 0.0005) from 2.5 (±0.3) to 1.2 (±0.4) in MMC
and from 2.6 (±0.2) to 1.4 (±0.3) in OLO group, with no intergroup differences (P = 0.08).
Six (30 %) cystic thin avascular blebs without oozing were recorded in the MMC group and 2 (10 %) in the
OLO group, without intergroup difference (P = 0.235).
Conclusions: Our extended follow-up results confirm that Ologen implant yields efficacy and long-term
success rates quite similar to MMC, with at least equivalent safety.
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Background
Trabeculectomy with mitomycin-C (MMC) today is still
regarded as the gold-standard in glaucoma surgery. Yet,
in many studies MMC-related complications such as
prolonged wound leaks, hypotony with choroidal effu-
sions and maculopathy, thin avascular blebs, and/or bleb
leaks with late infection are frequently reported [1–9].
A biodegradable collagen-glycosaminoglycan copoly-
mer matrix implant (Ologen®) has been proposed as an
alternative adjuvant, used as a spacer to mechanically
separate the sub conjunctival and episcleral tissues to
preventing fibrosis, and also helps in reorganizing the
subconjunctival scar formation.
In fact, it should induce fibroblasts and myofibroblasts
to grow randomly into its porous structure and secrete a
loose connectival matrix, reducing the scarring degree.
The implant is recommended to be placed subconjunc-
tivally over the scleral flap posteriorly and possibly a
small portion covering the scleral flap, else the ologen
disc would act as a mechanical tamponade and prevent
fluid outflow from the sub scleral space.
In 2010, a medium-term RCT did not show any intra-
ocular pressure-lowering advantage of the Ologen-
augmented trabeculectomy vs trabeculectomy alone,
with a higher yet not significant incidence of complica-
tions with the collagen implant [10]. In the same year
another randomized study of MMC-augmented trabecu-
lectomy vs trabeculectomy using Ologen showed a lower
complete success rate but a lower bleb-associated com-
plication rate in Ologen group [11].
In 2011, we published the results of a 24-month, ran-
domized prospective clinical trial on Ologen implant vs
MMC in trabeculectomy [12]. The intraocular pressure
(IOP) reduction was significant at endpoint in all groups
(P = 0.01). The rates and Kaplan–Meier curves did not
differ for both complete and qualified success at any tar-
get IOP. The bleb height in the Ologen-treated group
was higher than in the MMC one (P < 0.05). No adverse
reaction to Ologen was noted.
In the past three years, a number of clinical studies have
compared the efficacy and tolerability of trabeculectomy
augmented with Ologen versus trabeculectomy plus
MMC, with somehow contradictory results [13–20].
To obtain more data on the long-term IOP lowering
effect of the Ologen implant compared to MMC as adju-
vant in trabeculectomy, we extended to five years the
follow-up on the same cohort of subjects of our above-
said study. The parameters measured included IOP, bleb
morphology, and frequency of complications.
Methods
This study is an extended, 60-month follow-up data.
The protocol of the randomized study had been ap-
proved by the Ethical Committee of the University
Hospital of Palermo (Italy) on December 2007 and regis-
tered under the number 08/07 (12 September 2007) .We
reviewed the records of 40 patients who had been ran-
domly assigned to undergo a trabeculectomy with MMC
(MMC group) or a trabeculectomy with Ologen implant
(OLO group) for primary open-angle (POAG) or pseu-
doexfoliative glaucoma (PEXG) at the Department of
Ophthalmology of the University of Palermo. The data
used to generate the 5-year life table analysis were col-
lected over the interval between enrollment in the study
and 60 months following surgery.
In the previous prospective randomized clinical trial
[12] a sample size of 40 patients (20 eyes in each group)
had been chosen to achieve a power of 90 % for detect-
ing a 3-mmHg difference in IOP between treatment pro-
cedures, assuming a standard deviation of three mmHg
and a two-sided α error of 5 %.
In accord with tenets of Declaration of Helsinki a writ-
ten informed consent has been obtained from all patients,
also covering approval to publish images. We screened for
uncontrolled glaucoma 65 consecutive Caucasian patients
at the Glaucoma Center of the Department of Ophthal-
mology between January and December 2008. Sealed en-
velope technique from surgical chart number was used to
ensure randomization just before surgery. Skilled ophthal-
mologists and optometrists masked to randomization col-
lected the clinical data and the outcomes. Inclusion
criteria were age 18 or older, diagnosis of POAG or PEXG
with mild to moderate visual field damage [21], IOP above
21 mm Hg or visual field deterioration on maximum-
tolerated medical therapy.
Exclusion criteria were advanced glaucoma or split fix-
ation on visual field, normal-tension glaucoma, use of
medications for acute or chronic disease that could
affect the outcomes (eg, immunodeficiency, connective
tissue disease, and diabetes), clinically significant cata-
ract, previous ocular trauma or surgery. Included
preoperative data consisted of age, gender, type of glau-
coma, type and number of antiglaucoma medications;
the ophthalmic examination included Goldmann appla-
nation tonometry, biomicroscopy; Snellen visual acuity
and computerized Humphrey visual field testing (Hum-
phrey Visual Field Analyzer; HFA; Carl Zeiss Meditec.
Inc.).
The primary outcome was IOP evaluated at three dif-
ferent IOP target levels: ≤ 21, ≤17, and ≤15 mmHg.
Complete and qualified success were defined as usual,
i.e. without medications in the first case and regardless
of medications in the second one. Secondary outcome
measures included visual acuity (VA), mean deviation
(MD) change by Humphrey 24-2 full threshold testing,
bleb evaluation according to Moorfields Bleb Grading
System (MBGS), and bleb SD-OCT analysis. Number of
glaucoma medications and frequency of postoperative
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adjunctive procedures and complications were also
evaluated.
Surgical technique and follow-up
The technique has been described in detail in the previ-
ous study [12]. All operations, carried out by one experi-
enced surgeon (SC), included a superior fornix-based
conjunctival/tenons flap, with a rectangular scleral flap
at the 12-o’clock position, fashioned according to the
‘Moorfields Safer Surgery System’ procedure [22, 23].
When MMC (Kyowa S.r.l., Milan, Italy) was the random-
ized adjunctive therapy, Weck-cell sponge pieces soaked
with 0.2 mg/ml MMC were simultaneously placed under
the dissected conjunctiva/tenon surrounding the scleral
flap [22, 23], and on the scleral bed, underneath the
scleral flap, for a total time of 2 min [24]. After thorough
irrigation, trabeculectomy was performed with a
Crozafon-De Laage punch. A peripheral iridectomy was
performed, the anterior chamber was filled with visco-
elastic device, and the scleral flap was closed with two
minimally tensed 10-0 nylon sutures -one at each cor-
ner- in MMC cases and with one long and loose stitch
in OLO cases. A cylindrical Ologen implant (model
number 830601, Aeon Astron Europe BV), 2.0 ± 0.3 mm
in height x 6.0 ± 0.5 mm in diameter was then centered
over the top of scleral flap and underneath the conjunc-
tiva in the latter leaving the limbal end of the stitch par-
tially uncovered. The implants used in this cohort of
patients consisted of porcine based lyophilized cross-
linked type I atelocollagen (≥90 %) and glycosaminogly-
cans (≤10 %). Degradation time of this type was around
180 days. A newer version with exactly the same com-
position but with a bit shorter degradation time is now
available.
The conjunctival flap was secured to the limbus with a
tight 10-0 nylon running suture with buried knots.
Postoperatively, all eyes were treated with tapering doses
of topical tobramycin 0.3 % and dexamethasone drops
0.1 % for 2 months. The ‘intensified postoperative care’
(IPC) protocol [25] was followed in all cases and included
more frequent topical steroid administration if corkscrew
bleb vessels were present. Instillation of 1 % atropine
drops during the first few days was based on the hypotony
degree. Adjunctive procedures included the Carlo
Traverso maneuver [26], laser suture lysis or bleb needling
of encapsulated blebs (without antimetabolites).
If postoperative IOP measurements were >21 mmHg
after topical steroid withdrawal, IOP-lowering medica-
tion was added.
When, during the extended follow-up, a patient devel-
oped a clinically significant cataract in the operated eye,
a standard sutureless cataract surgery was performed
through a temporal 2.5-mm near-clear corneal tunnel
incision with a precalibrated knife (Clearcut, Alcon Italia
S.P.A., Milan, Italy). Phacoemulsification was performed
with the Alcon Infiniti Vision System (Alcon Italia
S.P.A.), using the Ozil torsional handpiece in the major-
ity of cases, avoiding any contact with the bleb area. The
implantation of acrylic hydrophobic foldable intraocular
lenses (IOLs) was performed using an Unfolder Emerald
injector system (AMO Italy, Rome, Italy) or a Monarch
II injector (Alcon Italia S.P.A.). The surgical wound was
closed by stromal hydration. All patients received topical
ofloxacin (Exocin, Allergan SpA, Rome, Italy) for 3 days
preoperatively and tobramycin and dexamethasone oph-
thalmic suspension (Tobradex, Alcon Italia S.P.A.) for
one week postoperatively, followed by nepafenac oph-
thalmic suspension (Nevanac, Alcon Italia S.P.A.) or
bromfenac ophthalmic solution (Yellox, Bausch Lomb,
Italia), for 3 weeks. In case of topical antiglaucomatous
therapy use, this was continued even throughout the
cataract surgery period. Even in cataract surgery cases, if
postoperative IOP measurements were >21 mmHg after
topical steroid withdrawal, IOP-lowering medication was
added.
Expanded follow-up implied six-monthly examinations
till the 60th month. All patients were thoroughly in-
formed about the importance of a periodical examin-
ation, and were regularly visited by the same staff to
create a relationship of empathy. We were lucky to be
able to follow all patients for 5 years. We report data
collected at 36, 48 and 60-month observation times
(Additional file 1).
Follow-up visits included assessment of VA, IOP,
biomicroscopic findings, number of antiglaucomatous
medications, and postoperative complications. Signs of
inflammation, such as cells and flare, were graded
from 0 to 4. The MBGS [27] -using recorded photo-
graphs- was used for bleb grading by a single observer
(GC) at each follow-up visit. Cystic or avascular blebs
were noted.
Spectral domain optical coherence tomography (SD-
OCT; Topcon 3DOCT-1000, Topcon Corporation,
Tokyo, Japan), already performed at the previous study
end point (24 month), was repeated at the 60-month ob-
servation time for bleb evaluation by ophthalmologists
masked to clinical data (CG and LLF). A bleb was identi-
fied as successful or failed based on the presence or ab-
sence of bleb wall thickening and microcystic or
hyporeflective intrableb wall structures (with respect to
a ≤17 mmHg target IOP level [28, 29]). Thereafter, we
add measurements of some bleb parameters, performed
with calipers using the device’s built-in software in a
masked fashion. Bleb wall thickness was defined as the
distance between the first reflective signal from the con-
junctiva to the top of the sub-Tenon fluid space. Because
the bleb wall thickness may vary along the scan, we ana-
lyzed only the maximum and minimum distances [30].
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The whole bleb height was defined as the maximum
vertical length from the outer margin of the bleb wall
and the highly reflective margin of the scleral surface in
the cross-sectional image.
Statistical analysis
Statistical analysis of quantitative and qualitative data, in-
cluding descriptive statistics, was performed for all items.
The independent Student t-test and the Mann–Whitney
U statistic test were used for parametric and non-
parametric analysis, respectively. Discrete variables were
analyzed using the chi square test and Fisher exact test, as
needed. Intragroup parametric and non-parametric ana-
lysis were carried on by using the paired-samples Student
t-test and paired Wilcoxon signed-rank test respectively.
Success was evaluated on the basis of Kaplan–Meier cu-
mulative probability (log-rank test). To assess intraobser-
ver reproducibility and consistency, an internal quality
control system was established before the study onset by
using three consecutive independent interpretations of the
same SD-OCT scan, together with the unweighted Cohen
kappa (k) test [31]. Data were analyzed by the Epi Info
software (version 6.0, Centers for Disease Control and
Prevention, Atlanta, GA, USA) and IBM SPSS Software
21.0 version (SPSS, Inc., Chicago, Ill, US). All P-values
were two-sided and P-values less than 0.05 were consid-
ered statistically significant.
Results
Patients in the two treatment groups did not signifi-
cantly differ in any of the preoperative parameters. Two
women with early-onset glaucoma, aged 36 and 38 years,
were included, the former in the MMC group and the
latter in the OLO one.
As above said, all 40 patients completed the 60-month
follow-up. During the 3rd to 4th year of follow-up, 3 cases
(15 %) in the MMC group and 2 cases (10 %) in the OLO
group developed a clinically significant cataract with VA
decrease in the operated eye, and therefore underwent
cataract surgery with IOL implantation (Table 1).
Mean Snellen acuity and visual field test MD at the 5-
years end point did not differ from the baseline in both
groups (Table 1). The mean preoperative IOP (±SD) was
26.5 (±5.2) in MMC eyes and 27.3 (±6.0) in OLO eyes,
without significant intergroup difference. One-day post-
operatively, the IOP dropped to 5.2 (±3.5) and 9.2 (±5.5)
mmHg, respectively (P = 0.009). No intergroup differ-
ence was present at any scheduled postoperative time
interval. The postoperative IOP reduction was significant
at the 24-month endpoint in both groups (P = 0.01). At
the extended 36-month time interval, the mean IOP was
15.6 (±2.6) in the MMC group and 15.9 (±2.5) mmHg in
the OLO group (P = 0.706), while at the 48th month the
IOP values were 15.9 (±2.6) and 15.3 (±3.4) respectively
(P = 0.563) Finally, at the 60th month the IOP values
were 15.2 (±3.2) and 15.8 (±2.3) respectively (P = 0.579).
The endpoint percentage IOP reduction from baseline
was 40.9 (±14.2) and 42.1(±13.3), respectively (P = 0.827)
(Table 2 and Fig. 1). The two cases of early-onset glau-
coma exhibited an IOP within the low teens without
medications.
In the cases who underwent cataract phacoemulsifica-
tion, the mean pre-operative IOP was 16.9 (±2.3) in
MMC eyes and 17.0 (±2.9) in OLO ones, whilst the end-
point IOP was 17.2 (±2.5) and 16.5 (±2.7) respectively
Table 1 Preoperative characteristics of patients who underwent trabeculectomy, Snellen acuity and MD change, and 3rd to 4th year
follow-up cataract surgery cases
MMC group OLO group P
Gender (M/F), N° 11/9 12/8 1.0a
Age, yrs. (mean ± SD) 63.2(7.2) 65.8(6.4) 0.234b
Right/left eyes, N° 7/13 11/9 0.340a
Type of glaucoma (POAG/PEXG), N° 12/8 13/7 1.0a
Preoperative IOP,mmHg (mean ± SD) 26.7(5.2) 27.3(6.0) 0.736b
Baseline CDVA, decimal notation 0.8 (±0.33) 0.75 (±0.31) 0.624
Endpoint CDVA, decimal notation 0.8 (±0.40) 0.8 (±0.35) 1.0
Baseline MD,dB (mean ± SD) -7.80(4.57) -7.41(5.35) 0.805b
Endpoint MD,dB (mean ± SD) -7.60(4.3) -7.50(5.6) 0.949b
Preoperative medications,N° (mean ± SD) 2.5(0.3) 2.6(0.2) 0.222b
Duration of preoperative antiglaucoma therapy,yrs. (mean ± SD) 5.7(1.8) 6.3(1.4) 0.246b
Cataract surgery cases 3 (15 %) 2 (10 %) 1.0
aChi square test or Fisher exact test, as needed; bindependent Student t test;
MMC =Mitomycin-C; OLO = Ologen; SD = standard deviation;
POAG = primary open angle glaucoma; PEXG = pseudoexfoliation glaucoma; CDVA = Corrected Distance Visual Acuity; MD = Humphrey Visual Field Analyzer
Mean deviation.
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(P = 0.885, and P = 0.875, respectively). The number of
antiglaucoma medications, 0.7 (0.6) in MMC and 0.5
(0.7) in OLO cases did no change after cataract surgery.
All cataract patients experienced a post-operative VA in-
crease of at least 2 lines.
Table 3 reports the success rates in the study groups.
At the 60-month endpoint follow-up, the values regard-
ing complete success at ≤ 21 mmHg target IOP were
65 % and 70 % respectively for the MMC and the OLO
group, with a qualified success of over 85 % in both. At
the ≤17 mm Hg target IOP, complete success percent-
ages were 60 % and 55 %, and qualified ones 70 % and
75 % respectively. At the ≤15 mm Hg target IOP level
complete success was recorded in 35 % and 45 % of
cases, and qualified one in 40 % and 50 % of patients
respectively with no significant difference at any follow-
up time.
At 24-month follow-up, the Kaplan–Meier cumulative
survival curves relating either the ≤21, ≤17, or ≤15 mmHg
target IOP had not showed significant intergroup differ-
ences for complete or qualified success rates. Figure 2, in-
dicates the same parameter behavior relating complete
success rates at ≤ 15 mm Hg target IOP up to the 60th
month end point, with no significant intergroup difference
(log-rank P = 0.595).
The area, height and vascularity MBGS scores did not
generally differ on an intragroup and intergroup basis,
maintaining stability till the 24th month. One exception
was height, whose mean score was higher in OLO group
at the third month (2.0 ± 0.8 vs 1.3 ± 0.7; P = 0.009;
Mann–Whitney U statistic test), maintaining a higher
yet not significant value till the first 24th month end
point.
No significant difference was found between the 24-
month and the 60-month values, either with respect to
central area (P = 0.729 in MMC and P = 0.231 in OLO
group), maximal area (P = 0.769 and P = 0.395, respect-
ively) and height (P = 0.408 and P = 0.478, respectively).
The 60-month mean MBGS score values in MMC vs
OLO group were 2.7 ± 0.7 vs 2.3 ± 0.9 (P = 0.191) relating
Table 2 Postoperative IOP (mmHg) in the surgical groups.
Mean (±SD; 95%CI); % change in IOP from baseline
MMC group OLO group Pa
3rd month 14.7(3.9; 12.9-16.4) 15.0(3.8; 13.3-16.7) 0.806
44.5 % 45.1 %
6th month 14.7(4.3; 12.7-16.6) 14.1(3.1; 12.6-15.4) 0.615
44.5 % 48.4 %
12th month 15.0(3.0; 13.6-16.4) 15.2(2.8; 13.8-16.4) 0.828
43.4 % 44.3 %
24th month 16.0(2.9; 14.6-17.4) 16.5(2.1; 15.5-17.4) 0.536
39.6 % 39.5 %
36th month 15.6 (2.6; 14.3-16.9) 15.9 (2.5; 14.6-17.2) 0.706
39.8 % 40.2 %
48th month 15.9 (2.6; 14.5-17.2) 15.3 (3.4; 13.4-17.1) 0.563
38.8 % 42.3 %
60th month 15.2 (3.2; 13.4-16.9) 15.8 (±2.3; 14.4-17.1) 0.579
41.0 % 42.1 %
a Independent Student t test; MMC =Mitomycin-C; OLO = Ologen;
SD = standard deviation
Fig. 1 Box-plot representation of IOP values over 60-months follow-up: median values (dark lines), error standard (T-bars)
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central area, 2.9 ± 0.8 vs 2.6 ± 1.0 (P = 0.378) relating
maximal area, and 1.2 ± 0.5 vs 1.2 ± 0.8 (P = 0.722) relat-
ing height, without intergroup difference. At the same
time interval, central, peripheral, and non-bleb vascularity
mean score values in MMC vs OLO group were 0.6 ± 0.3
vs 0.9 ± 0.5, 1.3 ± 0.3 vs 1.1 ± 0.3, and 1.6 ± 1.0 vs 1.4 ± 1.0,
with intergroup difference (P = 0.027; P = 0.041; P = 0.531),
respectively, relating the central and peripheral score.
Figure 3 shows two cases with diffuse bleb, one from
MMC and the other from OLO group, with a central
avascular/cystic area in the former and almost normal vas-
cularity in the latter.
There was high intraobserver reproducibility for SD-
OCT analysis (k = 0.7403, 95 % CI: 0.70–0.86). Table 4
reports the successful bleb frequencies, with respect to a
≤17 mmHg target IOP level, at 5-year follow-up.
Figure 4 displays examples of bleb thickness parame-
ters obtained using the SD-OCT built-in software at the
60-month end point. Eight eyes, 6 in the MMC and 2 in
the OLO group, with a cystic thin bleb, exhibited mini-
mum bleb wall thickness mean values significantly
smaller (54.5 ± 14.9 μ) than the remaining eyes (134.2 ±
17.3 μ) (P = 0.004), in agreement with the clinical ap-
pearance. No differences were found in terms of whole
bleb height between groups (140.5 ± 20.3 μ vs 129.2 ±
19.3 μ respectively; P = 0.079).
The mean number of antiglaucoma medications was sig-
nificantly reduced at end point in both groups (P < 0.0005
in both cases): from 2.5 (±0.3) to 1.2 (±0.4) and from 2.6
(±0.2) to 1.4 (±0.3) in the MMC and OLO groups, respect-
ively, without significant intergroup differences (P = 0.08).
The Carlo Traverso maneuver was employed in two
patients in each group between the 1st and the 14th
postoperative day. Four cases (20 %) in the MMC group
and three cases (15 %) in the OLO group -without inter-
group difference- underwent Laser suture lysis between
the first and the second postoperative week. Bleb need-
ling was performed from one to four times in seven
(35 %) and six (30 %) patients respectively, again without
intergroup difference.
The frequency of early postoperative complication did
not significantly differ between the two groups, even if a
tendency toward more frequent early bleb leakage was
noted in the OLO group, and toward more frequent early
hypotony, defined as an intraocular pressure (IOP) equal
to or less than 6 mmHg at the first postoperative day, and
choroidal detachment in MMC one. No adverse reaction
to the Ologen implant, matrix extrusion, or conjunctival
erosion was present in OLO group. At the 60-month end-
point, three more cases of clinically significant cataract
with VA decrease, 2 in the MMC and 1 in the OLO group,
were found, to a total of 5 and 3 cases respectively during
the whole follow-up. Five (25 %) patients in the MMC
group and 4 (20 %) in the OLO one experienced > 1 line
VA loss due to cataract or to age-related macular degener-
ation (AMD). Six (30 %) cystic thin avascular blebs with-
out oozing, as above said, were recorded in the MMC
group and 2 (10 %) in the OLO group, without intergroup
difference (P = 0.235) (Table 5).
Discussion
Both early and long-term complications are still reported
in MMC-augmented trabeculectomy: As pointed out in
our previous study [12], factors such as flaps fashioning,
suturing technique and prolonged fibroblast inhibition
Table 3 Success rates (%) at the 60-month follow-up study
endpoint in the surgical groups at three target IOP levels
MMC group OLO group Pa
≤21 mmHg
Complete success 13(65 %) 14(70 %) 1.0
Qualified success 17(85 %) 18(90 %) 1.0
≤17 mmHg
Complete success 12(60 %) 11(55 %) 1.0
Qualified success 14(70 %) 15(75 %) 1.0
≤15 mmHg
Complete success 7(35 %) 9(45 %) 0.747
Qualified success 8(40 %) 10(50 %) 0.751
aFisher exact test; MMC =Mitomycin-C; OLO = Ologen
Fig. 2 Kaplan-Meier cumulative probability curve of complete
success (without medications) at ≤15 mmHg target IOP in MMC
(solid line) vs OLO group (dotted line) (log-rank P = 0.595) at 60 month
follow-up. MMC=Mitomycin-C; OLO=Ologen
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-with thin bleb leaking- are responsible for these prob-
lems [8, 9, 22, 23, 32].
In our previous study, the early postoperative hypotony
rate is really quite high in both groups, probably due to
the loose stitches without fashioning releasable sutures:
the latter technique could avoid this complication [12].
Anyway, the reduced tendency to first postoperative day’s
hypotony in the OLO cases, when compared with the
MMC ones, can be explained as a mechanical Ologen-
induced aqueous outflow modulation.
The extended 5-year results indicate that the postoper-
ative IOP behavior is quite similar in both groups, with a
highly significant and stable IOP reduction, stable VA
and MD, and reduced administration of antiglaucoma
medications throughout the 60-month follow-up, with-
out intergroup differences. The equivalence in efficacy of
OLO vs MMC is further confirmed by their endpoint
success rates at the three different target IOP levels.
Even if it is well known that phacoemulsification leads
to an increased risk of bleb failure of approximately
33 %, with changes in bleb morphology and elevation in
IOP of 2-3 mmHg [33], in our cases the temporal access
phaco did not show any effect until the endpoint. The
exiguous number of cases could explain this finding.
The sample size power was calculated for the IOP
endpoint. Therefore, no conclusions can be drawn from
the secondary endpoints, e.g. bleb morphology, number
of postoperative medications and frequency of complica-
tions. We judge anyway that our results imply some in-
teresting observations. Testifying to the persistence of
the implant, the bleb height score was higher in the
OLO than in MMC group at the 3rd month. Indeed, the
residual implant volume added to the fluid-filled bleb
spaces could justify this finding (since its biodegradation
-according to the manufacturer- can last a 6-month
period as above said). It is possible that a larger sample
could have confirmed this difference in height for a lon-
ger period.
In studies using either morphologic grading scale
evaluation or experimental 3D anterior segment SD-
OCT, bleb height is one of the parameters correlated
with a lower IOP [28, 34–36]. Whether at 24-months or
60-months follow-up, our sample shows that the outer
bleb morphology by SD-OCT was quite similar between
groups. These findings imply that outer layers of a func-
tioning bleb are not modified by the OLO implant on a
Fig. 3 Slit light and diffuser photographs of two cases. Patient a (top): 38 yrs-old woman from MMC group. a diffuse bleb with central avascular/
cystic area can be seen. Patient b (bottom): 52 yrs-old man from OLO group. A diffuse bleb with almost normal vascularity is present
Table 4 60th month bleb success rates(%) at ≤17 mmHg target
IOP in the surgical groups according to the SD-OCT analysis
MMC
group60th
mo
OLO
group60th
mo
P60th
mo
Successful bleb / eyes with
complete success
10/12 9/11 1.0a
Failed bleb / eyes without
complete success
6/8 7/9 1.0a
SD-OCT sensitivity 83 % 82 % 0.627b
SD-OCT specificity 75 % 78 % 0.669b
aFisher exact test; bChi-square test for the comparison of two proportions
(from independent samples), expressed as a percentage;
MMC =Mitomycin-C; OLO = Ologen
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long term basis. In summary, the OCT bleb data indi-
cate that bleb morphology is disappointingly not
strongly correlated with function. A larger sample size
could perhaps reveal that the SD-OCT pattern of a suc-
cessful bleb, represents a prognostic factor for longer-
term success. The end point bleb wall SD-OCT analysis
confirms the critically reduced thickness of cystic thin
blebs in both groups. The similarity of the whole bleb
height in both groups, as measured by SD OCT, is in
agreement with the above said clinical judgment by
MBGS criteria.
The two groups did not differ with respect to adjunct-
ive postoperative procedures. This could once more con-
firm similarity between the adjuvants.
Similar rates of early complications in the two groups
further corroborate the equivalence of the effect of the
two adjuvants during this postoperative period. The
above said tendency to 1st day greater hypotony in
MMC eyes did not reach significance in our sample. The
low complication rate with low-dosage MMC within 2 years
is in agreement with our previous studies [24, 37–39]. The
cataract and AMD incidence could be ascribed both to
aging and to glaucoma surgery in our cases. As previously
noted, late thin avascular blebs are relatively common with
MMC use. In our sample, after 5 years MMC cases exhibit
a reduced vascularity together with a trend toward more
frequent thin blebs, confirming the long-term effect from
fibroblast mitosis inhibition [40]. It is surprising that, be-
sides vascularity, in our sample there is no difference in end
point bleb morphology of MMC cases when compared to
the OLO ones, especially taking into account the diffuse
area of application of MMC in the former and the limited
surface of the 6x2 mm Ologen implant in the latter (see
Fig. 3). The Ologen volume could hypothetically lift the sur-
rounding conjunctiva from the scleral bed for a while,
allowing a diffuse bleb, and/or, our sample size could imply
some biased results, as above stated.
Earlier short to medium term retrospective or pro-
spective randomized clinical trials denied our good re-
sults with Ologen. In fact, drawbacks such as lower bleb
height and higher vascularity in OLO group, with a
lower success rate, or higher complication rate of the
Ologen-augmented trabeculectomy with respect to the
simple one, or lower complete success rate even though
a lower bleb-associated complication rate in Ologen vs
MMC groups, are reported [10, 11, 41]. Variations in
surgical procedure could justify these different out-
comes. For instance, a non running suture with only two
Fig. 4 SD-OCT imaging of blebs at the 60-month end point with complete success based on≤ 15 mmHg target IOP. (a): Thick bleb from OLO group.
(b): Thin bleb from MMC group. The bleb (a), from the OLO group, exhibited a more diffuse pattern
Table 5 Frequency (%) of 60-month postoperative complications
in the surgical groups
MMC group OLO group Pa
Cataract 5(25 %) 3(15 %) 0.694
Age-related macular degeneration 2(10 %) 2(10 %) 1.0
Loss > 1 line VA 5(25 %) 4(20 %) 1.0
Thin avascular bleb 6(30 %) 2(10 %) 0.235
aFisher exact test; MMC =Mitomycin-C; OLO = Ologen
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10-0 nylon at the flap extremities likely lead to a higher
rate of positive Seidel test with flat anterior chamber.
Also, it could have reduced the role of the implant in
bleb development in one study [10]. Additionally, the
same study included 1-month topical steroid administra-
tion, vs 2 months with variable regimen based on IPC
criteria in our study. This difference could have freed
the vascular reaction in OLO eyes as aforementioned,
resulting in an excess of fibroblasts surrounding the im-
plant with higher end point IOP [10]. Finally, we note
that small sample sizes, techniques of application and
concentration of MMC, postoperative therapeutic regi-
men as well as variations in composition and different
manufacturers of Ologen implants over the years
could also be important factors to take into consider-
ation [11, 12, 19, 41]. On the other hand, the differ-
ence between our results and those obtained by other
centers in Germany, Singapore and India, could de-
rive from the long-time known racial difference in the
response to trabeculectomy, with white Caucasian
performing better than Hispanic, East-Asian or Black
population. The fibroblasts response to the Ologen
implant could well follow this behavior [42, 43].
A one-year prospective interventional multicenter
study including 30 eyes undergone trabeculectomy with
MMC (0.2 mg/mL, 0.1 mL)-soaked Ologen, concludes
that the procedure does not seem to exert any synergis-
tic effect in terms of IOP reduction [20]. We note that,
besides the lack of a control group, the MMC soaked
Ologen can be by itself the cause of "ring of steel" bleb,
due to the prolonged MMC localized effect with exces-
sive surrounding fibroblast proliferation [23].
Conversely, the results of our study are in agreement,
relating efficacy and safety, with recent shorter term studies
comparing Ologen-augmented vs MMC-augmented trabe-
culectomy [14–18].
In particular, Johnson et al [17] in a 12-month retro-
spective review find that Ologen allows for similar suc-
cess rates as MMC comparing respectively 49 vs 50 eyes
of mainly POAG patients undergoing a filtering proced-
ure using an Ex-PRESS (Alcon, Fort Worth, TX) mini
glaucoma device.
A recent systematic review and meta-analysis indicates
that trabeculectomy with Ologen is a safe and effective
procedure in patients with glaucoma, and is comparable
with MMC in IOP-lowering efficacy, even if does not
seem to offer any significant advantages compared with
trabeculectomy plus MMC [13].
Under this respect, especially considering the add-
itional cost to the Ologen implant when compared to
MMC, much larger trials are required to confirm pos-
sible advantages in terms of reduced incidence of early
hypotony and late avascular-thin blebs. Once these re-
quirements are met, the Ologen could be recommended
as an alternative to MMC, at least in those cases where
a target IOP in low teens is unnecessary. In the latter in-
stance, an association between both adjuvants could be
interesting.
Conclusions
Our long-term study confirms that the OLO implant
demonstrates efficacy in terms of IOP reduction, with a
success rate quite similar to MMC, and at least equiva-
lent safety. Moreover, outpatient surgery could benefit
from this adjuvant if the lack of early significant hypot-
ony will be confirmed by larger trials. Limits related to
the small sample size must be overcome by further lar-
ger randomized trials to confirm the efficacy and safety
of this device, and to accurately estimate any reduced
risk for avascular and thin blebs with respect to MMC.
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